Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 142

1.

Resveratrol and P-glycoprotein inhibitors enhance the anti-skin cancer effects of ursolic acid.

Junco JJ, Mancha A, Malik G, Wei SJ, Kim DJ, Liang H, Slaga TJ.

Mol Cancer Res. 2013 Dec;11(12):1521-9. doi: 10.1158/1541-7786.MCR-13-0237. Epub 2013 Sep 26.

4.

Macelignan: a new modulator of P-glycoprotein in multidrug-resistant cancer cells.

Im YB, Ha I, Kang KW, Lee MY, Han HK.

Nutr Cancer. 2009;61(4):538-43. doi: 10.1080/01635580802666273.

PMID:
19838926
5.

Farnesiferol A from Ferula persica and galbanic acid from Ferula szowitsiana inhibit P-glycoprotein-mediated rhodamine efflux in breast cancer cell lines.

Hanafi-Bojd MY, Iranshahi M, Mosaffa F, Tehrani SO, Kalalinia F, Behravan J.

Planta Med. 2011 Sep;77(14):1590-3. doi: 10.1055/s-0030-1270987. Epub 2011 Apr 11.

PMID:
21484672
6.

Inhibition of P-glycoprotein activity by limonin and other secondary metabolites from Citrus species in human colon and leukaemia cell lines.

El-Readi MZ, Hamdan D, Farrag N, El-Shazly A, Wink M.

Eur J Pharmacol. 2010 Jan 25;626(2-3):139-45. doi: 10.1016/j.ejphar.2009.09.040. Epub 2009 Sep 24.

PMID:
19782062
7.
8.

Quinoline derivative KB3-1 potentiates paclitaxel induced cytotoxicity and cycle arrest via multidrug resistance reversal in MES-SA/DX5 cancer cells.

Koo JS, Choi WC, Rhee YH, Lee HJ, Lee EO, Ahn KS, Bae HS, Ahn KS, Kang JM, Choi SU, Kim MO, Lu J, Kim SH.

Life Sci. 2008 Nov 21;83(21-22):700-8. doi: 10.1016/j.lfs.2008.09.009. Epub 2008 Sep 24.

PMID:
18845169
9.

Astragaloside Ⅳ reduces the expression level of P-glycoprotein in multidrug-resistant human hepatic cancer cell lines.

Wang PP, Xu DJ, Huang C, Wang WP, Xu WK.

Mol Med Rep. 2014 Jun;9(6):2131-7. doi: 10.3892/mmr.2014.2074. Epub 2014 Mar 27.

10.

Cyclosporin A has low potency as a calcineurin inhibitor in cells expressing high levels of P-glycoprotein.

Fakata KL, Elmquist WF, Swanson SA, Vorce RL, Prince C, Stemmer PM.

Life Sci. 1998;62(26):2441-8.

PMID:
9651111
12.

In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576.

Mistry P, Stewart AJ, Dangerfield W, Okiji S, Liddle C, Bootle D, Plumb JA, Templeton D, Charlton P.

Cancer Res. 2001 Jan 15;61(2):749-58.

13.

Specificity of doxorubicin versus rhodamine-123 in assessing P-glycoprotein functionality in the LLC-PK1, LLC-PK1:MDR1 and Caco-2 cell lines.

van der Sandt IC, Blom-Roosemalen MC, de Boer AG, Breimer DD.

Eur J Pharm Sci. 2000 Sep;11(3):207-14.

PMID:
11042226
14.

Role of the MDR-1-encoded multiple drug resistance phenotype in prostate cancer cell lines.

Theyer G, Schirmböck M, Thalhammer T, Sherwood ER, Baumgartner G, Hamilton G.

J Urol. 1993 Nov;150(5 Pt 1):1544-7.

PMID:
8105110
15.

Ursolic acid and resveratrol synergize with chloroquine to reduce melanoma cell viability.

Junco JJ, Mancha-Ramirez A, Malik G, Wei SJ, Kim DJ, Liang H, Slaga TJ.

Melanoma Res. 2015 Apr;25(2):103-12. doi: 10.1097/CMR.0000000000000137.

PMID:
25647735
16.

Increase in doxorubicin cytotoxicity by inhibition of P-glycoprotein activity with lomerizine.

Shiraki N, Hamada A, Ohmura T, Tokunaga J, Oyama N, Nakano M.

Biol Pharm Bull. 2001 May;24(5):555-7.

17.
18.
19.

Effect of Combined Treatment with Ursolic Acid and Resveratrol on Skin Tumor Promotion by 12-O-Tetradecanoylphorbol-13-Acetate.

Cho J, Rho O, Junco J, Carbajal S, Siegel D, Slaga TJ, DiGiovanni J.

Cancer Prev Res (Phila). 2015 Sep;8(9):817-25. doi: 10.1158/1940-6207.CAPR-15-0098. Epub 2015 Jun 22.

20.

Inhibition of P-glycoprotein-mediated paclitaxel resistance by reversibly linked quinine homodimers.

Pires MM, Emmert D, Hrycyna CA, Chmielewski J.

Mol Pharmacol. 2009 Jan;75(1):92-100. doi: 10.1124/mol.108.050492. Epub 2008 Oct 22.

Items per page

Supplemental Content

Write to the Help Desk